Pipeline dataset Lassa

Vaccine concept and antigen	Product developers /funders	Preclinical	Phase I	Phase II	Phase III
pLASV-GPC	United States Army Medical Research Institute for Infectious Diseases (USAMRIID), USA Inovio Pharmaceuticals				
ML29	Academic collaboration: Texas Biomedical Research Institute; Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, National Institutes of Health (NIH) Regional Bio-containment Laboratory, University of Louisville; Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands Medigen				
ML29 L-AttV	The Scripps Research Institute (TSRI), USA				
LassaVacc GPC	National Infection Service, Public Health England, Innovate UK				
VesiculoVax™	Profectus Biosciences with University of Yale (Pfizer license)				
VSVΔG/LASVGPC	Rocky Mountain Laboratories, NIH; University of Texas Medical Branch				
RABV-Lassa virus vaccine candidate GPC	National Institute of Allergy and Infectious Diseases (NIAID), NIH				
YF 17D GPC	Academic collaboration: Texas Biomedical Research Institute; Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, NIH Regional Bio-containment Laboratory, University of Louisville; Center for Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands Medigen				
MVA-VLP-TV vaccine (Haemorrhagic Fever Vaccine (Ebola, Sudan, Marburg, Lassa))	GeoVax, cooperation with USAMRIID since Feb-16				
Live attentuated rLCMV/CD	University of Rochester, The Scripps Research Institute				

GPC441-449 subunit	University of Vermont College of Medicine; The Scripps Research Institute, MWH Laboratories; La Jolla Institute of Allergy and Immunology, University of North Carolina—Chapel Hill School of Medicine, PaxVax, Inc., University of California				
LASV VLP	Tulane University Health Sciences Center; Autoimmune Technologies, LLC; Corgenix Medical Corporation; Vybion, Inc.,; U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, USA.				
HLA-A02 and 10 HLA-A03-restricted epitopes	La Jolla Institute for Allergy and Immunology, The University of Vermont College of Medicine, University of California, Pharmexa-Epimmune				
VaxCelerate subunit	Massachusetts General Hospital, EpiVax, Inc.; 21st Century Biochemicals, University of Washington, MPI Research, Pfenex Inc.				

This pipeline reflects, to the best of our knowledge as at August 2017, publicly available information on the status of vaccine candidates with a direction towards human use for Lassa fever. Please contact info@cepi.net if you have evidence to report on updates to this.